Table 1.

Characteristics of WHO EC trials using LNG

Trial	EC regimen used in trial	Participating centres in countries	Number of LNG cases included in this analyses (sample size)
A. Hong Kong 1993 [4] A prospective randomized comparison of LNG with Yuzpe regimen; Delay 0–48 h	Two LNG 0.75-mg doses with 12-h interval	1 centre in Hong Kong	410 (440)
B. WHO 1998 [5] RCT of LNG versus Yuzpe regimen; Delay 0–72 h	Two LNG 0.75-mg doses with 12-h interval	21 centres in 14 countries	974 (1001)
C. WHO 2002 [6] Low-dose mifepristone and two regimens of LNG; Delay 0–120 h	One LNG 1.5 mg dose Two LNG 0.75-mg doses with 12-h interval	15 centres in 10 countries	2695 (2756)
D. Nigeria 2010 [7] A randomized double-blind study to compare two regimens of LNG; Delay 0–120 h	One LNG 1.5 mg dose Two LNG 0.75-mg doses with 12-h interval	7 centres in Nigeria	2794 (3022)
Total pooled data	One LNG 1.5 mg dose Two LNG 0.75-mg doses with 12-h interval	31 centres in 17 countries	6873 (7219)